Table 12. Methodological quality of RCTs evaluating bevacizumab for indirect comparison.
Study | Comparability of groups | Adequate blinding | Definition of expected AE | Definition of method used to collect AE data | Transparency of patient flow | Validity safety |
Sacu et al. 2009 [26] | in part | open label | no | no | yes | low |
Costagliola et al. 2010 [27] | not specified | not specified | no | no | unclear | low |
ABC Trial 2010 [28] | in part | double blind | in part | in part | yes | moderate |
AE: Adverse effects.